Parkinson s disease treatment

Ahlskog JE. The Parkinson s disease treatment book. Partnering with your doctor to get the most from your medications. New York Oxford University Press, 2005. 

Parkinson s disease Treatment of idiopathic or postencephalitic Parkinson s disease. 

E.-K. Tan (2003). Dopamine agonists and their role in Parkinson s disease treatment. Exp. Rev. Neurotherap. 3 805-810. 

Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson s disease treatment. Lancet 2000 355 1333-1334. 

Pezzoli, G. Canesi, M. Pesenti, A. Mariani, C.B. (1995) Pergolide mesylate in Parkinson s disease treatment. J. Neural. Transm. Suppl 45, 203-212. 

Cardiovascular Does the patient have atrial fibrillation, a coronary artery disease history, or hyperlipidemia increasing stroke risk Could orthostatic hypotension be due to medications for Parkinson s disease treatment Is a medication such as amantadine causing peripheral edema ... 

An Algorithm (Decision Tree) for the Management of Parkinson s Disease Treatment Guidelines. Neurology 1998 50 (suppl 3) S1-S57. 

V.N. (2001) Structural insight into Parkinson s disease treatment from drug-inhibited DOPA decarboxylase. Nat. Struct. Biol. 8, 963-967. 

Marino MJ, Williams DL Jr, O Brien JA et al (2003) Allosteric modulation of group III metabotropic glutamate receptor 4 a potential approach to Parkinson s disease treatment. Proc Natl Acad Sci USA 100 13668-13673... 

Zeolite membranes are amenable by surface modification with a variety of chemical functional groups using simple silane chemistry that may provide alternative surface chemistry pathways for enzyme immobilization. In this context, Shukla et al. [338] have recently used a chemically modified zeolite-clay composite membrane for the immobilization of porcine lipase using glutaraldehyde to provide a chemical linkage between the enzyme and the membrane. The effects of pH, temperature, and solvent on the performance of such biphasic zeolite-membrane reactors have been evaluated in the hydrolysis of olive oil to fatty acids. Similarly, Algieri et al. [339] have immobilized tyrosinase on FAU membranes for the enzymatic conversion of the 1-tyrosine to 1-DOPA as an effective drug for Parkinson s disease treatment. This approach combines the active role of zeolite membrane as enzyme support and inhibitor suppressor. Moreover,... 

Pyridoxal phosphate enzymes have been targets of therapeutic interventions. Abnormal pulsatile stimulation of striatal dopamine receptors leads to dysregnla-tion of genes and proteins in downstream nenrons and, conseqnently, alterations in neuronal firing patterns. These result in the motor complications associated with Parkinson s disease. Treatment of Parkinson s disease aims to restore normal dopaminergic transmission at striatal synapses. Levodopa slows the progression of Parkinson s disease and has a prolonged effect on the symptoms of the disease. 

---